Daiichi Sankyo settles kickback allegations for $39 million; Whistleblower receiving $6.1M

Published



WASHINGTON (Legal Newsline) – Daiichi Sankyo, Inc., a pharmaceutical company, has agreed to pay federal and state Medicaid programs more than $39 million over allegations that it used kickbacks to entice physicians into prescribing its medications, the U.S. Department of Justice said on Friday.

The settlement is the result of a whistleblower lawsuit filed by Kathy Fragoules, a former Daiichi employee who alleged the New Jersey-based firm provided entertainment such as dinners and paid speaking engagements to doctors in exchange for their prescribing patients the company’s drugs. The medications included Azor, Tribenzor, Welchol and Benicar. 

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.